LONG-TERM SAFETY OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS

Silvio Danese  1     Bruce A. C. Cree  2     Douglas C. Wolf  3     OLGA ALEKSEEVA  4     Lorna Charles  5     AnnKatrin Petersen  5     James K. Sheffield  5     Chun-Yen Cheng  5     Jon V. Riolo  5     Diego Silva  5     Fred D. Lublin  6     Jeffrey A. Cohen  7     David T. Rubin  8    
1 Humanitas University, Milan, Italy
2 Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, United States
3 Atlanta Gastroenterology Associates LLC, Atlanta, United States
4 Nizhny Novgorod Regional Clinical Hospital, Nizhniy Novgorod, Russian Federation
5 Bristol Myers Squibb, Princeton, United States
6 Mount Sinai Medical Center, New York, United States
7 Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, United States
8 University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing